BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 37916308)

  • 21. Igniting Hope for Tumor Immunotherapy: Promoting the "Hot and Cold" Tumor Transition.
    Wei C; Ma Y; Wang F; Liao Y; Chen Y; Zhao B; Zhao Q; Wang D; Tang D
    Clin Med Insights Oncol; 2022; 16():11795549221120708. PubMed ID: 36147198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity.
    Piovesan D; Tan JBL; Becker A; Banuelos J; Narasappa N; DiRenzo D; Zhang K; Chen A; Ginn E; Udyavar AR; Yin F; Paprcka SL; Purandare B; Park TW; Kimura N; Kalisiak J; Young SW; Powers JP; Schindler U; Sivick KE; Walters MJ
    Mol Cancer Ther; 2022 Jun; 21(6):948-959. PubMed ID: 35405741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells.
    Zhang PF; Wang C; Zhang L; Li Q
    Immunotherapy; 2022 Apr; 14(6):459-473. PubMed ID: 35232284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death.
    Bao X; Xie L
    J Exp Clin Cancer Res; 2022 Jul; 41(1):222. PubMed ID: 35836249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment.
    Cekic C; Linden J
    Cancer Res; 2014 Dec; 74(24):7239-49. PubMed ID: 25341542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blocking LTB
    Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
    Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adenosine can thwart antitumor immune responses elicited by radiotherapy : Therapeutic strategies alleviating protumor ADO activities.
    Vaupel P; Multhoff G
    Strahlenther Onkol; 2016 May; 192(5):279-87. PubMed ID: 26961686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A defect in KCa3.1 channel activity limits the ability of CD8
    Chimote AA; Balajthy A; Arnold MJ; Newton HS; Hajdu P; Qualtieri J; Wise-Draper T; Conforti L
    Sci Signal; 2018 Apr; 11(527):. PubMed ID: 29692361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
    J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adenosine in cancer immunotherapy: Taking off on a new plane.
    Zhang C; Wang K; Wang H
    Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):189005. PubMed ID: 37913941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
    Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
    J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors.
    Feola S; Hamdan F; Russo S; Chiaro J; Fusciello M; Feodoroff M; Antignani G; D'Alessio F; Mölsä R; Stigzelius V; Bottega P; Pesonen S; Leusen J; Grönholm M; Cerullo V
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extracellular purines and their receptors in immunoregulation. Review of recent advances.
    Sitkovsky MV
    Nihon Ika Daigaku Zasshi; 1998 Oct; 65(5):351-7. PubMed ID: 9808987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PI3Kδ/γ inhibitor BR101801 extrinsically potentiates effector CD8
    Yoon YN; Lee E; Kwon YJ; Gim JA; Kim TJ; Kim JS
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unlocking antitumor immunity with adenosine receptor blockers.
    Remley VA; Linden J; Bauer TW; Dimastromatteo J
    Cancer Drug Resist; 2023; 6(4):748-767. PubMed ID: 38263981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A
    Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M
    J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting Immunosuppressive Adenosine Signaling: A Review of Potential Immunotherapy Combination Strategies.
    Zahavi D; Hodge JW
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.
    Butt AQ; Mills KH
    Oncogene; 2014 Sep; 33(38):4623-31. PubMed ID: 24141774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetically Induced Tumors in the Oncopig Model Invoke an Antitumor Immune Response Dominated by Cytotoxic CD8β
    Overgaard NH; Principe DR; Schachtschneider KM; Jakobsen JT; Rund LA; Grippo PJ; Schook LB; Jungersen G
    Front Immunol; 2018; 9():1301. PubMed ID: 29930558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-targeted superantigens produce curative tumor immunity with induction of memory and demonstrated antigen spreading.
    Azulay M; Shahar M; Shany E; Elbaz E; Lifshits S; Törngren M; Friedmann A; Kramer R; Hedlund G
    J Transl Med; 2023 Mar; 21(1):222. PubMed ID: 36967382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.